Neumora Therapeutics (NMRA) Total Non-Current Liabilities (2022 - 2025)

Neumora Therapeutics has reported Total Non-Current Liabilities for 4 years, with the latest figure at $45.7 million in Q3 2025.

• For the quarter ending Q3 2025, Total Non-Current Liabilities rose 43.88% year-over-year to $45.7 million; the trailing twelve-month figure through Sep 2025 stood at $45.7 million (up 43.88% YoY), and the FY2024 full-year result was $29.9 million, up 10.84% from the prior year.
• Total Non-Current Liabilities for Q3 2025 stood at $45.7 million, up from $40.9 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $45.7 million in Q3 2025, with the low at $23.1 million in Q2 2024.
• Average Total Non-Current Liabilities over 4 years is $31.6 million, with a median of $29.9 million recorded in 2024.
• Year-over-year, Total Non-Current Liabilities dropped 6.27% in 2023 and surged 77.06% in 2025.
• Tracing NMRA's Total Non-Current Liabilities over 4 years: stood at $28.8 million in 2022, then slipped by 6.27% to $27.0 million in 2023, then rose by 10.84% to $29.9 million in 2024, then jumped by 52.82% to $45.7 million in 2025.
• The last three Total Non-Current Liabilities figures came in at $45.7 million (Q3 2025), $40.9 million (Q2 2025), and $29.9 million (Q4 2024), per Business Quant data.

Peer Comparison